Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis

Rheumatology

Volumn 47, Issue 4, 2008, Pages 481-483

  Keat, Andrew C ^a   Gaffney, K ^b   Gilbert, A K ^a   Harris, C ^a   Leeder, J ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ankylosing spondylitis; Anti TNF; Biologic therapy; Employment; Socioeconomic; Work; Work disability

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENTEEISM; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DISEASE SEVERITY; DRUG RESPONSE; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; UNITED KINGDOM; WORK CAPACITY; WORK DISABILITY; WORK RESUMPTION; WORKING TIME; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG SCREENING; EMPLOYMENT; HOSPITALIZATION; MIDDLE AGED; MOTOR ACTIVITY; MULTICENTER STUDY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG EVALUATION; EMPLOYMENT; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MOTOR ACTIVITY; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WORK CAPACITY EVALUATION;

EID: 43049172347     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken010     Document Type: Article

References (29)

1. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum 2001;45:424-9.
2. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4-11.
3. Gobelet C, Luthi F, Al-Khodairy AT, Chamberlain MA. Work in inflammatory and degenerative joint diseases. Disabil Rehabil 2007;29:1331-9.
4. Chorus AMJ, Boonen A, Miedema HS, van der Linden S. Employment prospectives of patients with ankylosing spondylitis. Ann Rheum Dis 2002;61:693-9.
5. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: Results from the German rheumatological database. J Rheumatol 2000;27:613-22.
6. Boonen A, Chorus A, Miedema H et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-9.
7. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
8. Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:546-53.
9. Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
10. Braun J, Landewe R, Hermann KG et al. ASSERT Study Group.Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
11. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
12. van der Heijde D, Kivitz A, Schiff MH et al. ATLAS Study Group.Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54: 2136-46.
13. Brandt J, Marzo-Ortega H, Emery P. Ankylosing spondylitis: New treatment modalities. Best Pract Res Clin Rheumatol 2006;20:559-70.
14. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNFalpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6.
15. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
16. Davis JC Jr, Revicki D, van der Heijde DM et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis Rheum 2007;57:1050-7.
17. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
18. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
19. Braun J, Landewe R, Hermann KG et al. ASSERT Study Group.Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
20. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab. Rheumatology 2007;46:1450-3.
21. Jois RN, Gaffney K, Keat A. Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 2007;46:899-901.
22. McLeod C, Bagust A, Boland A et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
23. van der Heijde D, Han C, De Vlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
24. Keat A, Barkham N, Bhalla A et al. BSR Standards, Guidelines and Audit Working group. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939-47.
25. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
26. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
27. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
28. Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995;22:1609.
29. Doward LC, Spoorenberg A, Cook SA et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.